A probabilistic model for predicting hypoglycemia in type 2 diabetes mellitus: The Diabetes Outcomes in Veterans Study (DOVES)

Archives of Internal Medicine
Glen H MurataWilliam C Duckworth

Abstract

To develop and validate a method for estimating hypoglycemia risk in stable, insulin-treated subjects with type 2 diabetes mellitus. Subjects (n = 195) monitored their blood glucose levels 4 times daily for 8 weeks. An 8-week mean blood glucose value (GLUMEAN) with standard deviation (GLUSD) was derived for each patient. Subjects were then randomly allocated to a derivation or validation set. For the derivation set, we developed a logistic function based on GLUMEAN and GLUSD to describe the 8-week risk of hypoglycemia (blood glucose < or =60 mg/dL [3.3 mmol/L]). This function was used to assign a predicted probability of hypoglycemia to each subject in the validation set. Subjects were assigned to risk quartiles and followed up for up to 52 weeks. We evaluated 195 subjects, 95% of whom were men and 69% of whom were non-Hispanic white. For 72 derivation subjects, GLUMEAN and GLUSD were highly influential determinants of hypoglycemia during intensified monitoring. The 123 validation subjects were followed up for 39.7 +/- 7.1 weeks (mean +/- SD). The occurrence of long-term hypoglycemia differed significantly across risk quartiles (19.4%, 36.7%, 61.3%, and 77.4%, respectively; P<.001). Receiver operating characteristic curve analy...Continue Reading

Citations

Aug 21, 2013·Indian Journal of Endocrinology and Metabolism·Surabhi Venkata Satya KrishnaKirtikumar D Modi
Dec 11, 2007·Journal of General Internal Medicine·Michael E MathenyAlexander Turchin
Sep 10, 2008·Current Diabetes Reports·Christopher T Kodl, Elizabeth R Seaquist
Oct 18, 2013·International Journal for Quality in Health Care : Journal of the International Society for Quality in Health Care·Benjamas SirikamonsathianSomrat Lertmaharit
Oct 15, 2014·International Journal of Molecular Sciences·Yoshifumi Saisho
Jan 25, 2016·Reviews in Endocrine & Metabolic Disorders·L MonnierD R Owens
Oct 24, 2009·Health and Quality of Life Outcomes·Tom StargardtCharles M Alexander
Apr 28, 2017·PLoS Computational Biology·David J AlbersLena Mamykina
Oct 1, 2009·The Diabetes Educator·Christopher G ParkinWilliam H Polonsky
Aug 3, 2018·Diabetes Technology & Therapeutics·Keiichi TorimotoYoshiya Tanaka
Apr 30, 2015·Diabetes & Metabolism Journal·Suk Chon
Dec 8, 2009·Endocrine Reviews·Sarah E SiegelaarJ Hans DeVries
Aug 18, 2018·BMJ Open Diabetes Research & Care·Lisa S ChowPamela J Schreiner
May 13, 2011·Diabetes Technology & Therapeutics·Louis MonnierDavid Owens
Oct 14, 2014·Diabetic Medicine : a Journal of the British Diabetic Association·S-M JinJ H Kim
Mar 3, 2007·Southern Medical Journal·Patrick J Boyle, John Zrebiec
May 20, 2005·Endocrine Practice : Official Journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists·Dan Streja
Oct 28, 2018·Scientific Reports·Meaghan RempelJonathan McGavock
Mar 21, 2021·Diabetes & Metabolic Syndrome·Ramya RaviSivasankaran Ponnusankar
May 20, 2021·Journal of Feline Medicine and Surgery·Guido LinariFederico Fracassi

❮ Previous
Next ❯

Related Concepts

Related Feeds

Biomarkers for Type 2 Diabetes

Biomarkers can help understand chronic diseases and assist in risk prediction for prevention and early detection of diseases. Here is the latest research on biomarkers in type 2 diabetes, a disease in which the body is unable to produce or properly use insulin.